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capable of spontaneous reversion to a wild-type
phenotype in certain T-cell lines
Yudong Quan1, Hongtao Xu1, Victor G Kramer1, Yingshan Han1, Richard D Sloan1 and Mark A Wainberg1,2,3*Abstract
Background: Attempts to eradicate HIV from cellular reservoirs are vital but depend on a clear understanding of
how viral variants are transmitted and survive in the different cell types that constitute such reservoirs. Mutations in
the env gene of HIV may be able to exert a differential influence on viral transmission ability in regard to cell-free
and cell-associated viral forms.
Methods: The ability of HIV containing an env G367R mutation in cell-free and cell-associated viruses to cause infection and to
revert to wild-type was measured using several T cell lines. To determine factors that might potentially influence the reversion
of G367R, we studied each of entry inhibitors, inhibitors of cellular endocytosis, and modulators of cell growth and activation.
Results:We demonstrate that an HIV-1 variant containing a G367R substitution within the CD4 binding site of gp120 was
non-infectious as free virus in culture but was infectious when infected cells were co-cultured with certain T cell lines or
when cells were transfected by a relevant proviral plasmid. Differences in viral infectivity by cell-associated G367R viruses
were determined by the type of target cell employed, regardless which type of donor cell was used. Reversion was
slowed or inhibited by entry inhibitors and by inhibitors of cellular endocytosis. Interleukin 2 was able to block G367R
reversion in only one of the T cell lines studied but not in the other, while phorbol 12-myristate 13-acetate (PMA) inhibited
G367R reversion in all the T cell lines.
Conclusions: Env-defective HIV may have a different phenotype as cell-free versus cell-associated virus. The persistence of
defective forms can potentially lead to the emergence of virulent forms. The heterogeneity of cell types that constitute
the HIV reservoir can contribute to viral variability, even among similar types of cells. This is the first demonstration of
a mutation in the HIV envelope, i.e. G367R, that can compromise infection by cell-free virus but less severely by
cell-associated virus and that does so in a cell type-dependent manner.
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HIV-1 can be efficiently transmitted as free virus or dir-
ectly between cells via cell-cell contact, each of which
involves receptor and coreceptor binding. Although cell-
free HIV may be used to initiate new infections in tissue
culture, cell-to-cell transmission is considered to be
more physiologically relevant and efficient [1-4].* Correspondence: mark.wainberg@mcgill.ca
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unless otherwise stated.HIV-1 entry into target cells is believed to be a multistep
process initiated by binding between the envelope protein
gp120 and cell surface CD4. This binding then triggers
conformational changes of gp120 that lead to a second-
step interaction between gp120 and a coreceptor such as
CXCR4 or CCR5 [5-7], resulting in viral membrane fusion
with the cellular plasma membrane [8]. In addition to viral
proteins, several host proteins including the histocompati-
bility complex can influence HIV infectivity [9,10]. How-
ever, it has also been reported that HIV can enter target
cells via a CD4-independent or coreceptor-independent
mechanism [11-13], potentially broadening the spectrumtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HIV entry is complex and can involve different channels.
Meanwhile, the fitness of HIV is critical for transmis-
sion and pathogenesis. Unlike many viruses, HIV has
very high genetic variability and evolves quickly. The
viral population in an infected individual is highly het-
erogeneous. Therefore, HIV-1 infected individuals may
contain diverse viral swarms termed quasispecies that
are similar but genetically distinct [14,15]. Large num-
bers of mutations, including those responsible for drug
resistance, may exist in the viral population of infected
individuals [16]. A major proportion of human immuno-
deficiency virus among quasispecies may be defective
due to the spontaneous generation of lethal mutations.
However, defective proviral mutants may still be able to
play a role in HIV pathogenesis, e.g. through recombin-
ation and rescue of drug resistance phenotypes [17] and
viral recombination may take place with defective viral
forms among the quasispecies and increase viral fitness
as well as transmission. There are reports that a highly
infectious virus-producing cell line may contain five cop-
ies of the HIV genome, none of which is infectious indi-
vidually [18]. Increased efficiency of HIV transmission
may increase the likelihood that target cells become in-
fected by multiple virions and increase the chances of
viral recombination [19-22]. This, in turn, could facili-
tate viral escape from selection pressure by drugs and
the immune system [16,23].
In regard to transmission, the viral envelope protein is
not only responsible for viral entry but also modulates
certain functions of host cells that facilitate infection.
HIV pseudotyped with VSV-G cannot successfully infect
resting T cells [24] and mutations in the viral envelope
proteins may affect viral infectivity through different
mechanisms. Certain mutations, including those at posi-
tions G367R and D368R in the CD4 binding site
(CD4bs) of gp120, may cause the virus to become non-
infectious [17,25-27].
Most HIV research has involved the use of cell-free vi-
ruses, although it is known that it is easier to isolate
HIV from cocultures of infected lymphocytes than
plasma. Although the reasons for this are unclear, it is
possible that HIV variants that are harbored within cells
can be transmitted more efficiently than cell-free forms
at least until faster-growing viruses ultimately emerge.
We have previously documented that a substitution
in Env at position G367R can result in viral non-
infectiousness and that this deficit can be rescued by re-
combination. One of the purposes of the current study
was to further characterize this deficit and provide new
information on its physiological importance. In this
manuscript, we show that the defectiveness of the
G367R mutation is more severe in the context of free
virus than cell-associated virus, but only in certain typesof cells. We have studied the reversion of env-defective
mutants in several T cell lines and obtained different re-
sults with cell-free vs cell-associated viruses in regard to
env defectiveness. Here, we report that some env mu-
tants may perform differently in cell-free versus cell-to-
cell transmission and that a G367R mutant can spontan-
eously revert in some T cell lines. Viruses containing
this mutation, that is located within the CD4bs of
gp120, are non-infectious in culture when cell-free vi-
ruses are employed as reported previously [17]. We also
report that G367R reversion was slowed or inhibited by
HIV entry inhibitors, such as the gp120 binding agent
DS003 and the CXCR4 antagonist AMD3100, as well as
by inhibitors of endocytosis at sub-toxic concentrations.
Interestingly, interleukin 2 (IL2) can block G367R rever-
sion in MT2 cells but not in SupT1 cells, while PMA is
able to inhibit reversion in both cell types, suggesting
that complex mechanisms are involved in the reversion
process.Materials and methods
Cells
MT2, MT4, Jurkat, CEM, PM1 and SupT1 cells were all
obtained through the NIH AIDS Research and Reference
Reagent Program. All these cell types can efficiently support
CXCR4-dependent HIV replication, and both MT2 and
MT4 cells are standards for HIV replication studies. All
cells were maintained in RPMI 1640 medium (Invitrogen)
supplemented with 10% fetal bovine serum (Invitrogen),
1% L-glutamine, and 100 units/ml penicillin/100 μg/ml
streptomycin under 5% CO2 at 37°C. 293 T and TZM-bl
cells were maintained in Dulbecco modified Eagle medium
(Invitrogen). Culture media were changed every 3 days.Viruses
The HIV-1 HxB 2D clone was used as wild type (WT)
virus. A defective env G367R mutant virus was produced
by transfecting a proviral plasmid, that contained a muta-
tion at position G367R in the CD4 binding site of gp 120,
and that has been generated by PCR based site directed
mutagenesis [17]. pVPack-VSV-G (Stratagene), which en-
codes the vesicular stomatitis virus (VSV) envelope glyco-
protein, was used at 1:1 to produce VSV-G pseudotyped
viruses. G367R mutant viruses and VSV-G pseudotyped
viruses were generated in 293 T cells by transfection from
the proviral plasmids with lipofectamine 2000 as recom-
mended by the manufacturer (Invitrogen). At 48 hours
after transfection, viruses were harvested, analyzed for p24
antigen and stored at −80°C.
R5 tropic subtype C Indie viruses were generated in
293 T cells by transfection from the Indie C proviral plas-
mid [28], also using lipofectamine 2000 as recommended
by the manufacturer.
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Figure 1 p24 production in MT2 cells after infection by G367R
virus pseudotyped with VSV-G, G367R or wild type viruses.
3×105 MT2 cells were infected for 3 hours at 37°C, then washed
with medium, and split into 3 wells for growth.
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cord blood mononuclear cells (CBMCs), obtained through
our Hospital Department of Obstetrics. Virus stocks were
kept at −70°C until use.
Viral infection
2-5×105 cells were infected with 0.5 ml of culture fluid con-
taining ~500 ng of p24 of HIV for 3 hr at 37°C. Cells were
washed three times with RPMI 1640 medium immediately
following incubation to remove unbound virus and were
resuspended in RPMI 1640 medium and split into wells at
appropriate concentrations. Cytopathic effects (CPE) were
monitored by microscopy and supernatants were evaluated
for p24 antigen at 3 day intervals (Biomerieux, Netherlands).
For infection of 293 T or TZM-bl cells, 105 cells plated
the previous day were infected overnight by 0.5 ml of
VSV-G pseudotyped viruses. Supernatants were removed
and washed once and fresh medium was added. Super-
natants were collected and cells were split at 3 day inter-
vals and monitored for p24 antigen.
Viral infection by coculture
104 293 T or TZM-bl cells infected with pseudotyped
G367R virus in a donor coculture were mixed with 5×104
target cells. Alternatively, 105 MT4 cells infected with
pseudotyped G367R virus in a donor coculture were
mixed with 2-4×105 MT2 cells. CPE and levels of p24
antigen in supernatants were monitored to verify effi-
ciency of infection and reversion.
HIV inhibitors and endocytosis inhibitors
The HIV entry inhibitors AMD3100, maraviroc, and
DS003 were all obtained through the NIH AIDS Re-
search and Reference Reagent Program. The endocytosis
inhibitors chlorpromazine hydrochloride, Genistein and
methyl-β-cyclodextrin were purchased from Sigma-
Aldrich, Inc. Phorbol 12-myristate 13-acetate (PMA)
was purchased from Cayman Chemical, Ann Arbor, MI.
Results
The env mutant G367R is defective in cell-free infection
but can replicate and revert to wild type spontaneously
in the MT2 infected T cell line
We previously reported that viruses containing the env
mutant G367R are defective in cell-free infection [17],
similar to what has been observed for a mutation at pos-
ition 368, D368R [25-27]. Theoretically, expected rever-
sion rates should be about 10−5 at a given site in single
round infection studies, if the error rate of HIV reverse
transcriptase is estimated at around 5×10−4. Thus, rever-
sions might only be expected at a rate of 5×10−4, i.e., it
would only be observed in a proportion of experimental
studies when 105 cells or fewer are seeded after infection
at appropriate viral concentrations. However, we foundhigher reversion rates than expected when we employed
the defective G367R virus that was pseudotyped with
VSV-G and then used to infect MT2 cells (Figure 1 and
Table 1). Figure 1 shows that the increase in p24 in the
G367R-infected samples was slower than occurred when
WT virus was used to mediate infection. This is not un-
expected, considering that only a portion of cells are in-
fected in a single round infection because of defective
progeny viruses. However, CPE appeared in all the sam-
ples within 1–3 weeks, contrary to expectations. Rever-
sion was confirmed by the fact that the progeny viruses
gained the ability to participate in cell-free infections
during second round infection experiments. This was
demonstrated as well by documentation of a wild-type
genotype, as shown by sequencing of the viral env gene
(see below). In contrast, G367R alone (i.e., not pseudo-
typed) was noninfectious (Figure 1), consistent with our
previous report [17]. Similar results were obtained for all
samples tested over repeat experiments that involved
seeding either 5×104 or 104 infected cells (Table 1).
Thus, the reversion rate of G367R seems higher than the
RT error rate over a single round of infection. As a con-
sequence, we next investigated this phenomenon using a
number of different cell types.
The G367R reversion is both cell-type dependent and
viral infection dose-dependent
Four T cell lines, MT2, MT4, SupT1 and PM-1, were used
to investigate the mechanism(s) whereby G367R can
achieve reversion. All of these cells express both the CD4
receptor and the CXCR4 coreceptor, while PM-1 cells also
express the CCR5 coreceptor. Variable amounts of virus
and cell numbers were used in order to estimate the rever-
sion rate. The growth curves and extent of CPE of G367R
mutated virus in each of MT2, MT4, SupT1 and PM-1
cells are displayed in Figure 2 and in Table 1. The results
show that reversion of G367R was cell-type dependent,
Table 1 G367R + VSV-G reversion in different cell types
Cells and
numbers
Viruses used and time of appearance of CPE
G367R G367R + VSV-G
CPEa p24 CPE p24
MT2 105 Nob 0 8-12d (3/3)c >600 ng/mld
5×104 9-15d (6/6) >600 ng/ml
104 11-21d (24/24) >600 ng/ml
102 21d (16/16) >600 ng/ml
MT4 105 No 0 14d (2/3) >600 ng/ml
SupT1 104 No 0 21d (6/6) >600 ng/ml
5×102 35d (24/24) >600 ng/ml
PM1 104 No 0 (0/6) 0
Cells were incubated with viruses at 4-fold dilution for 3 hours, washed and
resuspended in fresh media, and split into wells at appropriate concentrations.
aCPE = cytopathic effect.
bNo = CPE not observed over 28 days.
cnumber (d = day) represents the time of first appearance of CPE in the last
sample analyzed over 28 days. Numbers (in parentheses) designate numbers
of wells in which CPE was observed.
devaluated during 28 days after infection. p24 values of CPE negative samples
were lower than listed.
Table 2 Dose dependent reversion of G367R + VSV-G in
MT2 and MT4
Cells and
numbers
Viruses used and time of appearance of CPE
Virus dilutiona G367R G367R + VSV-G
CPEb p24 CPE p24
MT2 104 4× (0/24)c 0 14d (24/24) >600 ng/mld
500 4× 14d (16/16) >600 ng/ml
500 12× 21d (14/16) >600 ng/ml
100 36× 28d (15/16) >600 ng/ml
MT4 105 4× (0/3) 0 14d (2/3) >600 ng/ml
5000 12× (0/3) <50 ng/ml
5000 36× (0/3) <50 ng/ml
MT2 or MT4 cells were incubated with viruses at different dilutions for 3 hours,
washed and resuspended in fresh media, and split into wells at appropriate
concentrations.
avirus dilution used for infection.
bCPE = cytopathic effect.
cnumber (d = day) represents the time of first appearance of CPE in the last
sample analyzed over 28 days. Numbers (in parentheses) designate the
numbers of samples in which CPE was observed.
devaluated during 28 days after infection. p24 values of CPE negative samples
were lower than listed.
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SupT1 cells but rarely in MT4 and PM-1 cells (Tables 1
and 2). The initial infection of MT4 by pseudotyped
G367R was successful on the basis of p24 value but viral
replication then decreased gradually while PM-1 cells
were not as sensitive to infection as MT4 or MT2 cells
(Figure 2). Sequencing of the env gene in all the reverted
MT2 and SupT1 cells, regardless the number of infected
cells that were seeded demonstrating that G367R had
reverted from GGA AGG GAC CCA to GGA GGG GAC
CCA, corresponding to a change in amino acid sequence
from GRDP to GGDP within the CD4 binding site (Table 3).
The time of reversion was closely related to the num-
bers of cells seeded after 3 hours of infection and the
seeding of higher numbers of cells in each well led to
faster reversion. Reversion of HIV from the same batch
of infected cells occurred within 2 weeks when 104 in-
fected cells were seeded but only after 3 weeks if 1000 5 10 15 20 25
0
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Figure 2 p24 production in MT2, MT4, SupT1 and PM-1 cells
after infection by G367R virus pseudotyped with VSV-G. Cells
were infected for 3 hours at 37°C, then washed with medium, and
105 cells were split into wells in triplicate for growth assays.infected cells were seeded (Table 1). Therefore, the re-
version rate in one round, based on an inoculum of 100
cells was at least 500-fold higher than that expected only
on the basis of the RT mutation rate and the estimation
that each cell is successfully infected by a single virus.
Otherwise, a single cell would need to be infected by
500 viruses simultaneously, representing an impossible
situation.
Virus concentration may also affect the rate and time
of reversion as shown in Table 2. Reversion appeared
faster in samples infected by higher rather than lower
amounts of virus. There was no reversion in MT4 cells
when diluted pseudotyped G367R was used to initiate
infection. This is reasonable because the fewer the vi-
ruses, the fewer infected cells in the first round. These
findings indicate that reversion of the mutant G367R
virus is unlikely to be generated over a single round of
infection and that multiple rounds of viral replication
may be needed in order to increase the chances for a re-
vertant to emerge.
Similar results to those obtained with PM-1 cells were
obtained with both Jurkat cells, CEM cells and CBMCs
when infected by the G367R mutant pseudotyped with
VSV-G (data not shown).
The G367R reversion is facilitated by viral transmission
between cells
To further investigate the mechanisms involved, we car-
ried out several experiments to eliminate interference, if
any, by the VSV-G protein and by HTLV-1 that is con-
stitutively produced by MT2 cells. First, MT2 cells were
directly transfected with the G367R proviral plasmid
Table 3 Sequences of reverted G367R env around CD4 binding site
HIV Env 365 366 367 368 369 370
HXB2D A AGA GAA CAA TTT GGA AAT AAT AAA ACA ATA ATC TTT AAG CAA TCC TCA GGA GGG GAC CCA GAA ATT GTA CGC
G367R A AGA GAA CAA TTT GGA AAT AAT AAA ACA ATA ATC TTT AAG CAA TCC TCA GGA AGG GAC CCA GAA ATT GTA CGC
R1-MT2 A AGA GAA CAA TTT GGA AAT AAT AAA ACA ATA ATC TTT AAG CAA TCC TCA GGA GGG GAC CCA GAA ATT GTA CGC
R2-MT2 A AGA GAA CAA TTT GGA AAT AAT AAA ACA ATA ATC TTT AAG CAA TCC TCA GGA GGG GAC CCA GAA ATT GTA CGC
R3-MT2 A AGA GAA CAA TTT GGA AAT AAT AAA ACA ATA ATC TTT AAG CAA TCC TCA GGA GGG GAC CCA GAA ATT GTA CGC
R1-SupT1 A AGA GAA CAA TTT GGA AAT AAT AAA ACA ATA ATC TTT AAG CAA TCC TCA GGA GGG GAC CCA GAA ATT GTA CGC
R2-SupT1 A AGA GAA CAA TTT GGA AAT AAT AAA ACA ATA ATC TTT AAG CAA TCC TCA GGA GGG GAC CCA GAA ATT GTA CGC
HXB2D represents wt, G367R represents the mutant plasmid, R1-3 represent the reverted viruses recovered, respectively, from G367R + VSV-G infected MT2 or
SupT1 cells when seeded at cell numbers of 105, 104 or 102.
Table 4 G367R infectivity in cell cocultures
Weeks G367R + VSV-G CPEa
MT2b: 105 MT4: 105
2c 293 T SNd -e -
Co + -
TZM-bl SN - -
Co + -
4 293 T SN - -
Co + -
TZM-bl SN - -
Co + -
6 293 T SN - -
Co + -
TZM-bl SN - -
Co + -
10 293 T SN - -
Co + -
TZM-bl SN + +
Co + +
293 T or TZM-bl donor cells were infected by pseudotyped G367R viruses. The
infected cells or supernatants were used to infect target cells at different
time points.
aCPE = cytopathic effect.
btarget cell type and numbers used for infection.
cnumber of weeks after infection of donor cells.
dSN = supernatants of infected donor cells were used for infection,
Co = coculturing target cells with infected cells at a ratio of 1:5.
e−designates that CPE was not observed over 14 days. + designates that CPE
was observed within 14 days.
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fected MT2 cells was comparable in terms of time re-
quired to that of infection by the VSV-G pseudotyped
G367R mutant, indicating that reversion does not seem
to be influenced by the VSV-G protein. The fact that
SupT1 cells infected by G367R pseudotyped with VSV-G
reverted in the same manner as seen with infection of
MT2 cells negates the likelihood that the HTLV-1 in the
MT2 cells contributed to the reversion. In support of
this, MT2 cells that were infected by R5 tropic subtype
C Indie viruses that had been pseudotyped with VSV-G
did not produce progeny that could infect MT2, MT4 or
SupT1 cells, because such progeny viruses are unable to
infect these cells in second round infections (data not
shown). Therefore, these results do not support the idea
that the HTLV-1 envelope protein can pseudotype with
HIV, since, HTLV-1 pseudotyped R5 viruses should also
be infectious were this to occur, consistent with our re-
cent report [29].
Finally, supporting evidence comes from results ob-
tained with 293 T and TZM-bl cells that were infected by
VSV-G pseudotyped G367R virus and then cocultured
with MT2 or MT4 cells. The results all indicate that rever-
sion requires viral transmission through a cell-to-cell
route, as shown in Table 4. MT2 cells cocultured with the
G367R positive 293 T or TZM-bl cells developed CPE
within about 1–2 weeks while the cells infected by G367R
positive supernatants did not. Reversion in the cocultured
MT2 cells was confirmed over a second round of cell-free
infection. In contrast, MT4 cells that were cocultured with
G367R positive 293 T or TZM-bl cells did not develop
CPE over a 4 week period. However, phenotypic reversion
did occur in the G367R positive TZM-bl cells that were
maintained for up to 10 weeks in culture, since both su-
pernatants and cocultures were infectious at the time
points that were tested (Table 4). In contrast, the infection
of 293 T cells did not lead to reversion on the basis of the
infectivity of supernatants and p24 values that decreased
at week 10 (data not shown). This indicates that G367R
mutant virus can infect or reinfect TZM-bl cells but can-
not infect 293 T cells.The spontaneous reversion of G367R mutant involves
cell-to-cell transmission and the efficiency of reversion is
determined by the type of target cell employed
Next, we investigated whether donor or target cells de-
termine the efficiency of reversion of the G367R mutant.
As shown above, coculturing G367R positive 293 T and
TZM-bl cells, but not their supernatants, with MT2 or
MT4 cells confirmed that the cell-associated the G367R
virus can infect MT2 cells and revert to WT but cannot
infect MT4 cells (Table 4). This result indicates that the
type of target cell is important in determining the
(a)
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Figure 4 p24 production in MT2 cells after infection by G367R
virus pseudotyped with VSV-G viruses in the presence of entry
inhibitors. MT2 cells were infected for 3 hours at 37°C, then washed
with medium, and 105 cells were split into wells in triplicate for
growth in the presence or absence of DS003 (a) or AMD3100 (b).
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http://www.virologyj.com/content/11/1/177reversion of G367R mutant. The fact that MT4 cells in-
fected by diluted G367R viruses that were pseudotyped
with VSV-G did not revert is also in agreement with this
result (Table 2). This finding also indicates that the mu-
tant G367R HIV-1 cannot transmit if MT4 cells serve as
both donor and target cells, as p24 values decreased
gradually (Figure 3). In contrast, MT4 donor cells can
transmit HIV-1 G367R mutant to MT2 target cells. In
our experiments, CPE appeared after about 3 weeks in
cocultures of MT4 cells containing G367R provirus, i.e.,
MT4 donor cells with uninfected MT2 cells. Reversion
of phenotype was confirmed by a steep increase in p24
values in culture fluids (Figure 3) and the ability of the
supernatants to participate in a second round of infec-
tion via cell-free transmission (data not shown). Thus,
the G367R mutant has no deficit in ability to bud from
MT4 cells. Moreover, it can be concluded that the effi-
ciency of the G367R reversion is completely determined
by the type of target cell used and not by donor cells.
Entry inhibitors can delay G367R reversion
To determine whether the observed reversion was related
to virus entry, three entry inhibitors were employed to de-
termine their effect on transmission and reversion. A
gp120 binding inhibitor DS003 and a CXCR4 inhibitor
AMD3100 were used in MT2 cultures infected by G367R
viruses pseudotyped with VSV-G. A CCR5 inhibitor Mara-
viroc was used as a control. The results showed that
DS003 was not able to inhibit G367R reversion when used
at a fairly low concentration, i.e. 2 nM, a concentration
around the IC50 (3.1 nM as determined in an assay of cell-
free infection with WT virus) (Figure 4a). However, DS003
was able to inhibit G367R reversion at concentrations of
20 nM and 200 nM, since the p24 values in culture super-
natants increased by day 14 and then decreased. In0 10 20 30 40
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Figure 3 p24 production in MT2-MT4 cell cocultures after
infection by G367R pseudotyped with VSV-G viruses. MT2 or
MT4 cells were infected for 3 hours at 37°C, then washed with
medium, and 105 cells were split into 2 wells for growth assays. 105
infected MT4 cells after 7 days from each well were split into 2 wells
and mixed with fresh 2×105 MT2 cells. Two curves are shown
separately because the values of the duplicate cocultures
were different.contrast, p24 values of all the samples tested after with-
drawal of DS003 at day 7, continued to increase (data not
shown) and CPE developed within 3 weeks. However,
these viruses developed resistance quickly since CPE ap-
peared in one of three experiments at each of 20 nM and
200 nM DS003 at 5 weeks after infection, accompanied by
an increase in p24 value (Table 5). The resultant progeny
was resistant to DS003 in a second round of cell-free in-
fection (data not shown).
The CXCR4 inhibitor AMD3100 also delayed rever-
sion but less efficiently (Figure 4b). A concentration of
180 μM that was 10,000 times above the IC50 of 7.8 nM
(as determined in an assay of cell-free infection
with WT virus) was needed to delay G367R reversion
(Figure 4b). Again, the virus developed resistance quickly
(5 weeks after infection) in one of three experiments
(Table 5). As expected, Maraviroc did not have any in-
hibitory effect. Taking together, it appears that G367R
reversion requires the entry of the G367R mutant into
cells and that replication must precede reversion. This
process can be inhibited by entry inhibitors.
Endocytosis inhibitors can delay G367R reversion
HIV binding to the viral receptor and coreceptor can
trigger viral fusion with the plasma membrane; however,
Table 5 Inhibition of G367R virus in MT2 cells by entry
inhibitors
Entry
inhibitor
Concentration Continuousa Withdrawal
CPEb p24 CPE p24
DS 003 2 nM 3/3c >600 ng/mld 3/3 >600 ng/mld
20 nM 1/3 variable 3/3 >600 ng/ml
200 nM 1/3 variable 3/3 >600 ng/ml
AMD3100 0.18 μM 3/3 >600 ng/ml 3/3 >600 ng/ml
18 μM 1/3 variable 3/3 >600 ng/ml
180 μM 1/3 variable 3/3 >600 ng/ml
Maraviroc 1.0 nM 3/3 >600 ng/ml 3/3 >600 ng/ml
10 nM 3/3 >600 ng/ml 3/3 >600 ng/ml
100 nM 3/3 >600 ng/ml 3/3 >600 ng/ml
MT2 cells were infected by pseudotyped G367R viruses at 4-fold dilutions and
grown in the presence of entry inhibitors. The cultures were then split into 2
wells at day 7 with only one of them being maintained in the presence
of inhibitors.
aContinuous represents the maintainance of the entry inhibitors in the
cultures. Withdrawal represents drug withdrawal after 7 days of infection.
bCPE = cytopathic effect.
cNumbers of samples in which CPE was observed over 5 weeks after infection.
devaluated during 28 days following infection. p24 values of CPE negative
samples were lower than listed.
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mechanism of HIV entry into cells is dependent on
endocytosis [30]. In order to explore whether the spread
of the G367R mutant virus might be affected by inhibi-
tors of endocytosis, we employed three such molecules
in our experiments, i.e., chlorpromazine which is
thought to inhibit clathrin-dependent (CDE) processes
as well as two clathrin-independent endocytosis(CIE)
inhibitors, i.e., Genistein and methyl-β-cyclodextrin
(MβCD). Genistein is a tyrosine-kinase inhibitor and
causes local disruption of the actin network at the site
of endocytosis while the mechanism of MβCD is to in-
hibit the endocytosis process that is dependent on the
integrity of lipid rafts.
All three inhibitors affected cell viability. Only a two-fold
higher concentration of chlorpromazine and Genistein re-
sulted in cell death in MT2 than in MT4 cells (data not
shown). Only one or two subtoxic concentrations of chlor-
promazine and MβCD as tested in 2-fold serial dilutions
permitted cell growth yet inhibited G367R virus replication
(Figure 5). 5 μg/ml of chlorpromazine slowed increases in
p24 values and reversion occurred in only in 2 of 4 experi-
ments after 25 days of infection. Lower concentrations of
drug did not inhibit viral reversion. A concentration of
2.5 μM MβCD slowed cell viral growth by about 2-fold and
delayed viral replication only slightly. Reversion appeared in
all 4 experiments after 25 days of infection (Figure 5b) and
lower concentrations of drug had no effect on viral rever-
sion. In contrast, subtoxic concentrations of Genistein
inhibited cell growth between 6-40 mM and cells became
larger and round, indicating that the drug disrupted thestructure of the cell skeleton. However, viral replication was
not depressed as much as cell growth because p24 values
increased even though the cells grew slowly. Reversion ap-
peared in almost all experiments after 25 days (Figure 5c).
These results indicate that the spread of the G367R mutant
requires the process of endocytosis and is related to CDE
but not to CIE, similar to WT HIV, because this process
was not inhibited by MβCD and was not affected as much
as Genistein-mediated inhibition of cellular replication.
Interleukin 2, PMA and ionomycin can block G367R
reversion differentially in varying T cell lines
Based on the above results, G367R reversion may be de-
termined by undefined cellular mechanisms. Contrary to
expectations, we found that IL2 was able to inhibit the re-
version of G367R virus in MT2 cells at the same concen-
tration used to maintain T lymphocyte growth (Figure 6a)
without affecting cell viability, while it only slightly inhib-
ited cell-free wt HIV by about 2 fold (data not shown). In
contrast, IL2 had no influence on the reversion of G367R
in SupT1 cells, based on both p24 measurements and
CPE (Figure 6a). Again, there was no growth or reversion
of G367R in MT4 cells, suggesting that a different mech-
anism of reversion of G367R may be involved in different
cells.
However, PMA and ionomycin inhibited the reversion
of G367R virus in both MT2 and SupT1 cells (Figure 6b).
A low concentration of PMA of 0.1 ng/ml or ionomycin
at 25 ng/ml both inhibited the G367R reversion. These
results suggest that the reversion of G367R that is
dependent on transmission between cells may be protein
kinase C (PKC) related.
Discussion
HIV uses two receptors for entry unlike other viruses
that employ only a single receptor. This double receptor
entry process may have evolutionary advantage and HIV
infection that occurs via a single receptor seems less effi-
cient [31]. Differences in ability to infect resting T cells
also exist between HIV-env dependent and independent
(i.e., pseudotyped) virus entry [16,24]. In contrast to
other HIV env mutants that can enter cells via CD4 in-
dependent mechanisms [11,31,32], we have discovered
an env mutant that is defective in regard to cell-free in-
fection but that can enter some target cells when cell-
associated. Indeed, the Env G367R virus seems to be
able to cause infection only as cell-associated virus.
This finding may shed light on the fact that HIV can
spread between cells in the presence of neutralizing anti-
bodies that might completely block the spread of cell-free
virus [33]. Although, CD4bs specific antibodies may be
ubiquitously elicited during natural infection [25,34-36],
they did not retain neutralization potency during cell-cell
viral transmission. HIV can escape antibody responses
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Figure 5 p24 production in MT2 cells after infection by G367R virus pseudotyped with VSV-G viruses in the presence of endocytosis
inhibitors. MT2 cells were infected for 3 hours at 37°C, then washed with medium, and 105 cells were split into four replicate wells for growth in
the presence or absence of chlorpromazine (a), MβCD (b) or Genistein (c).
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Figure 6 p24 production in MT2, MT4 and SupT1 cells after infection by G367R virus that had been pseudotyped with VSV-G viruses
in the presence of IL2, PMA or ionomycin. MT2 cells were infected for 3 hours at 37°C, then washed with medium, and 105 cells were split
into wells in triplicate for growth in the presence or absence of 20 IU/ml of IL2 (a), 0.1, 0.5 ng/ml of PMA or 25 ng/ml of ionomycin (b).
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G367R mutant is suggestive of conformational changes in
the env protein but the process of escape is not fully
understood. Previous studies showed that the CD4bs mu-
tation D368R within env lost affinity for neutralizing anti-
bodies and that the mutated viruses were also defective as
tested in cell-free infections [25-27].
Similar to what has been observed with the G367R
mutant, the blocking activity of CD4bs specific anti-
bodies largely compromises free virus but blocking activ-
ity is much less in cell-cell transmission, thus allowing
virus entry, replication and spread to occur. Partial or in-
complete inhibition of infection likely fosters the emer-
gence of mutants and escape as well as viral replication,
even though partial selection pressure is still maintained.
In vitro studies of the evolution of drug resistance have
reached similar conclusions, i.e., resistance may be more
common following cell-cell transmission. In support of
this, our data here and the results of others [33,42,43]
have shown that entry inhibitors can inhibit HIV cell-
cell spread but only at much higher concentrations than
are effective at blocking cell-free transmission.
Differences in sensitivity of G367R virus to entry in-
hibitors varied by 10–10,000-fold between cell-to-cell
transmission and cell-free transmission. G367R, like
D368R, changes the local structure around the CD4bs of
env, rendering the virus in cell-free form unable to bind
CD4. However, the fact that the mutant can still spread
in some cell types indicates that mutated env can retain
partial functionality under certain conditions, similar to
what can happen in the presence of CD4bs specific anti-
bodies or if cellular mechanisms can compensate for a
viral defect. Our cell-type dependent results are consist-
ent with recent results that cell line-based differences
can occur during cell-to-cell HIV-1 transmission [44].
However, free virus transmission must be an important
component of viral spread in infected individuals. Our
results demonstrate that selection pressure on free virus
transmission is pronounced to the point that 367R re-
verts to 367G quickly. Obviously, cell-to-cell transmitted
viruses must be dependent on free virus transmission to
reach anatomically distant sites. The fitness of 367G (i.e.
WT) virus is much higher than that of 367R in cell-free
as well as cell-to-cell transmission. Therefore, reversion
to 367G is the result of natural selection. This may ex-
plain why the G367R or D368R mutations have never
been observed as cell-free forms in infected individuals
or in tissue culture.
Cell-type differences may also explain why G367R can
spread between some cell types, e.g., MT2 and SupT1, but
not others. Our finding that a G367R reversion is cell type
dependent supports the idea that viral involvement in
cell-associated or cell-free transmission depends both on
the virus and target cell. Interestingly, MT2 and MT4 cellsare both highly sensitive to WT HIV in cell-free infection
but behave quite differently in regard to susceptibility to
the env mutant G367R in cell-associated entry. The fact
that the gp120 binding inhibitor DS003 and the CXCR4
inhibitor AMD3100 can inhibit G367R spread and that
the virus can revert in TZM-bl cells but not in 293 T cells
indicates that cell-associated transmission of G367R is a
receptor-related event. Our findings represent an example
of a situation whereby some env mutants such as G367R
may be defective in regard to receptor binding but that
this can be overcome by cellular mechanisms that com-
pensate and promote cell-associated defective virus to
slowly replicate, such that the latter can revert. It is im-
portant to note that our study was focused on the G367R
mutation in Env and relevant reversion at this site. Of
course, it will be important to analyze for other mutations
and/or reversions both in Env and in other regions of the
viral genome. Such work is complex and is in progress.
The cellular mechanisms underlying the rescue of
G367R are complex. MT4 cells are highly sensitive to
cell-free WT HIV but do not support cell-associated
G367R reversion. Although IL2 can stimulate T cell
growth and promote T cell line replication, an unex-
pected effect of IL2 in regard to G367R reversion was a
differential result in varying cell types. However, only IL-
2 slightly affected the replication of WT HIV as cell-free
virus. Blockage of reversion in MT2 cells is consistent
with reports that IL2 can inhibit HIV replication in
HTLV-1 transformed T cell lines [45], perhaps due to el-
evated APOBEC protein incorporation into virions.
However, our results with MT4 and SupT1 cells, both of
which are Vif permissive, i.e. APOBEC-negative, showed
that the G367R virus was able to revert in SupT1 but
not in MT4 cells. This suggests that an APOBEC-
independent mechanism may be involved and that dif-
ferent mechanisms of G367R reversion may be present-
ing MT2 vs SupT1 cells (Figure 6a). Protein kinase C
(PKC) may be involved in the reversion of G367R be-
cause the PKC modulator PMA and the Ca++ ionophore
ionomycin both inhibited G367R reversion in both MT2
and SupT1 cells (Figure 6b). Chronic PMA treatment of
T cell lines may down-regulate PKC [46]. However, PKC
is involved in a variety of cellular events and further
studies will need to be carried out to clarify the mecha-
nisms involved. We speculate that the HIV envelope
may be able to trigger different PKC-mediated events in
different cell types, leading to the differential results ob-
tained here, but this needs to be confirmed.
Our data raise the importance of HIV cell-associated
forms in the context of viral defectiveness, even in the ab-
sence of recombination. As yet undiscovered cellular
mechanisms may be involved and HIV may be more fit
than studies with cell-free HIV might suggest. It is known
that it is easier to isolate clinical viruses via coculture than
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reasons for this, the existence of defective mutants is
doubtless one of them.
HIV-infected cells in semen and cervico vaginal secre-
tions—especially infected macrophages and CD4+ T cells—
play an important role in the sexual transmission of HIV.
However, these cells have been largely overlooked in studies
of the mechanisms of HIV transmission as well as in the
design and testing of HIV vaccine and microbicide candi-
dates, that have mostly evaluated cell-free virus stocks
[47,48]. This explains why some candidates may not protect
against cell-associated viral transmission and the failure of
several vaccine and microbicide clinical trials.
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